336 related articles for article (PubMed ID: 31081526)
21. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
22. PARAFOVEAL CAPILLARY DENSITY AFTER PLAQUE RADIOTHERAPY FOR CHOROIDAL MELANOMA: Analysis of Eyes Without Radiation Maculopathy.
Say EA; Samara WA; Khoo CT; Magrath GN; Sharma P; Ferenczy S; Shields CL
Retina; 2016 Sep; 36(9):1670-8. PubMed ID: 27232466
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
[TBL] [Abstract][Full Text] [Related]
24. Radiation maculopathy treated with intravitreal bevacizumab.
Sánchez-Vicente JL; Muñoz-Morales A; Galván-Carrasco MP; Castilla-Lázpita A; Vital-Berral C; Alfaro-Juárez A; Rueda-Rueda T
Arch Soc Esp Oftalmol; 2017 Jun; 92(6):283-286. PubMed ID: 27894518
[TBL] [Abstract][Full Text] [Related]
25. Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs.
Ibrahim WS; Eldaly ZH; Saleh MG; Rateb MF; Aldoghaimy AH
Korean J Ophthalmol; 2019 Apr; 33(2):122-130. PubMed ID: 30977321
[TBL] [Abstract][Full Text] [Related]
26. Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin).
Gupta A; Muecke JS
Retina; 2008; 28(7):964-8. PubMed ID: 18698298
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization.
Wang JK; Huang TL; Chang PY; Chen YT; Chang CW; Chen FT; Hsu YR; Chen YJ
Sci Rep; 2018 Sep; 8(1):14389. PubMed ID: 30258077
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab.
Ebrahimiadib N; Lashay A; Riazi-Esfahani H; Jamali S; Khodabandeh A; Zarei M; Roohipoor R; Khojasteh H; Bazvand F; Ojani M; Shahabinejad M; Yaseri M; Modjtahedi BS; Davoudi S; Riazi-Esfahani M
Ophthalmic Surg Lasers Imaging Retina; 2020 Mar; 51(3):145-151. PubMed ID: 32211904
[TBL] [Abstract][Full Text] [Related]
29. Aflibercept for Radiation Maculopathy Study: A Prospective, Randomized Clinical Study.
Murray TG; Latiff A; Villegas VM; Gold AS
Ophthalmol Retina; 2019 Jul; 3(7):561-566. PubMed ID: 31277797
[TBL] [Abstract][Full Text] [Related]
30. Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration.
Sawada T; Wang X; Sawada O; Saishin Y; Ohji M
Clin Exp Ophthalmol; 2018 Jan; 46(1):46-53. PubMed ID: 28621038
[TBL] [Abstract][Full Text] [Related]
31. Monthly intravitreal bevacizumab for macular edema after iodine-125 plaque radiotherapy of uveal melanoma.
Mashayekhi A; Rojanaporn D; Al-Dahmash S; Shields CL; Shields JA
Eur J Ophthalmol; 2014; 24(2):228-34. PubMed ID: 23934823
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
Ogura Y; Roider J; Korobelnik JF; Holz FG; Simader C; Schmidt-Erfurth U; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
Am J Ophthalmol; 2014 Nov; 158(5):1032-8. PubMed ID: 25068637
[TBL] [Abstract][Full Text] [Related]
34. Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema.
Khattab AM; Hagras SM; AbdElhamid A; Torky MA; Awad EA; Abdelhameed AG
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1373-1380. PubMed ID: 31127381
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion in Chinese Patients.
Wang JK; Huang TL; Su PY; Chang PY; Tseng YY
Eye Sci; 2015 Jun; 30(2):63-6, 69. PubMed ID: 26902063
[TBL] [Abstract][Full Text] [Related]
36. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
Morimoto M; Matsumoto H; Mimura K; Akiyama H
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
[TBL] [Abstract][Full Text] [Related]
37. Intravitreal aflibercept for myopic choroidal neovascularization.
Pece A; Milani P
Graefes Arch Clin Exp Ophthalmol; 2016 Dec; 254(12):2327-2332. PubMed ID: 27286893
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
[TBL] [Abstract][Full Text] [Related]
39. One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study.
Pak KY; Shin JP; Kim HW; Sagong M; Kim YC; Lee SJ; Chung IY; Park SW; Lee JE
Ophthalmologica; 2020; 243(4):255-262. PubMed ID: 31914437
[TBL] [Abstract][Full Text] [Related]
40. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
Jørstad ØK; Faber RT; Moe MC
Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
